Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
08 August 2024 - 10:00PM
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical
company focused on the development and commercialization of
therapeutics for central nervous system (CNS) disorders, today
announced that Sharon Mates, Ph.D., Chief Executive Officer and
Chairman, is scheduled to present at the Canaccord Genuity 44th
Annual Growth Conference on Tuesday, August 13, 2024 at 12:00 p.m.
ET in Boston, MA.
The live and archived webcast can be accessed under
"Events & Presentations" in the Investor Relations section of
the Company's website at www.intracellulartherapies.com. Please log
in approximately 5-10 minutes prior to the event to register and to
download and install any necessary software.
About Intra-Cellular
TherapiesIntra-Cellular Therapies is a biopharmaceutical
company founded on Nobel prize-winning research that allows us to
understand how therapies affect the inner-workings of cells in the
body. The company leverages this intracellular approach to develop
innovative treatments for people living with complex psychiatric
and neurologic diseases. For more information, please visit
www.intracellulartherapies.com.
Contact:Intra-Cellular Therapies,
Inc.Juan Sanchez, M.D.Vice President, Corporate Communications and
Investor Relations646-440-9333
Burns McClellan, Inc.Cameron Radinovic
cradinovic@burnsmc.com 646-930-4406
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Oct 2024 to Nov 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Nov 2023 to Nov 2024